Literature DB >> 9839283

Therapeutic implications and new perspectives for essential hypertension and renal damage.

O González-Albarrán1, R García Robles, L M Ruilope.   

Abstract

The kidney can suffer the consequences of a persistently elevated blood pressure. In fact end-stage renal failure caused by essential hypertension appears to be one of the most prevalent etiologies in patients entering a dialysis program. Blood pressure control is needed in order to prevent the progressive loss of renal function. Target blood pressure control has been established at values as low as 125/75 mm Hg for patients with proteinuria above 1 g/day. Attainment of this target level usually requires the combination of two or more drugs. However, the possibility that differences exist among the different classes of antihypertensive drugs beyond their capacity to simply lower blood pressure remains to be clearly elucidated. The fact that the presence of chronic renal failure is also accompanied by an enhanced cardiovascular risk potentiates the need to explore the renoprotective and cardiovascular protective capacity of the different classes of antihypertensive drugs, in patients with essential hypertension and some degree of renal involvement, characterized by the presence of microalbuminuria, proteinuria and/or an elevated serum creatinine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9839283     DOI: 10.1046/j.1523-1755.1998.06812.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  2 in total

1.  Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients.

Authors:  R Bitar; O Flores; M Reverte; J M López-Novoa; J F Macías
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

2.  Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials.

Authors:  Rui Xu; Shanmei Sun; Yan Huo; Lin Yun; Shuai Huang; Guohua Li; Suhua Yan
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.